Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)

Sponsor
University of Hull
Study ID
NCT05646199
Phase
PHASE2/PHASE3
Status
Unknown

Conditions

  • Polycystic Ovary Syndrome

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 45 Years
Healthy Volunteers
Not accepted

Interventions

  • Metformin — DRUG
    Participants will receive metformin
  • Semaglutide Injectable Product — DRUG
    Participants in this group will receive injectable Semaglutide

Study Details

The goal of this clinical trial is to compare the effect of Semaglutide and metformin on weight loss in obese women with Polycystic Ovarian Syndrome (PCOS) over a 28-week treatment period. The main question it aims to answer is: • Which of the 2 drugs, metformin or Semaglutide causes more weight loss when used over a 28 week treatment period in obese women with PCOS? Participants will be divided into 2 groups by chance. In the first group, participants will be asked to take metformin orally. In the second group, participants will take Semaglutide by injection under the skin weekly. The maximum duration of participation for the patients in the trial is 32 weeks. Researchers will compare the weight reduction, quality of life and individuals' wellbeing between the two groups.

Key Dates

Start date
Mar 1, 2025
Status verified
May 2024
Primary completion
Sep 30, 2025
Completion
Dec 30, 2025

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Metformin
    Participants in this group will be given metformin
  • Active Comparator: Semaglutide
    Participants in this group with receive Semaglutide

Primary Outcome Measure

Weight loss (kg) [ Time Frame: 28 weeks ]

Central Contacts

Related Studies